Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Toxoplasmosis in AIDS].

C Leport1, J S Remington

  • 1Service des Maladies infectieuses et tropicales, Hôpital Bichat-Claude Bernard, Paris.

Presse Medicale (Paris, France : 1983)
|July 4, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

2010 French SPILF-AFSSAPS guiding criteria for Streptococcuspneumoniae acute community-acquired pneumonia: Evaluation in patients of the PACSCAN-ESCAPED cohort.

Infectious diseases now·2020
Same author

Multi-sectorial research is paramount for preventing and controlling emerging infectious diseases.

Revue d'epidemiologie et de sante publique·2019
Same author

Community-acquired pneumonia in the emergency department: an algorithm to facilitate diagnosis and guide chest CT scan indication.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2019
Same author

Diabetes and dyslipidaemia are associated with oxidative stress independently of inflammation in long-term antiretroviral-treated HIV-infected patients.

Diabetes & metabolism·2019
Same author

Need for integrative thinking to fight against emerging infectious diseases. Proceedings of the 5th seminar on emerging infectious diseases, March 22, 2016 - current trends and proposals.

Revue d'epidemiologie et de sante publique·2017
Same author

The French Infectious Diseases Society's readiness and response to epidemic or biological risk-the current situation following the Middle East respiratory syndrome coronavirus and Ebola virus disease alerts.

Medecine et maladies infectieuses·2017
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Toxoplasmosis is a significant opportunistic infection in HIV patients, often causing encephalitis. Research focuses on effective treatments and primary prophylaxis to prevent relapses in this vulnerable population.

Area of Science:

  • Infectious Diseases
  • Parasitology
  • HIV/AIDS Research

Context:

  • Toxoplasmosis is a major opportunistic infection in HIV-infected individuals, particularly in France, affecting 15-37% of patients.
  • Encephalitis is the most common manifestation, though chorioretinitis, pneumonia, and disseminated disease also occur.
  • Lifelong treatment is crucial for HIV patients to prevent toxoplasmosis relapses.

Purpose:

  • To outline current treatment strategies for toxoplasmosis in HIV-infected patients.
  • To highlight the need for novel anti-parasitic drugs for human use.
  • To emphasize the importance of primary prophylaxis research in managing toxoplasmosis in immunocompromised individuals.

Summary:

  • Conventional treatment involves pyrimethamine and sulfadiazine for at least 3-8 weeks, with pyrimethamine-clindamycin as an alternative.

Related Experiment Videos

  • Maintenance therapy uses lower doses of the same drugs to prevent recurrence.
  • Ongoing research aims to develop new drugs and effective primary prophylaxis methods.

    • Impact:

    • Informs clinical practice regarding toxoplasmosis management in HIV patients.
    • Guides future research directions for drug development and preventative strategies.
    • Aims to improve patient outcomes and reduce the incidence of opportunistic infections in immunocompromised populations.